Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
All right. So thanks, everyone, for joining us this morning at the Goldman Sachs Global Healthcare Conference. Really pleased to be joined by the team at Arrowhead Pharmaceuticals, giving us an update on where things are, where things are headed for their RNAi platform.
Questions & Answers
So let's start at the beginning of that level. How should we think about Arrowhead's RNAi approach and how it's differentiated versus peers in the landscape?
Sure. So thanks for having us, Madhu, and thanks to everybody, the Goldman team. So our Arrowhead's RNAi platform, we call it TRiM or targeted RNAi molecules. And the idea behind TRiM is that these are simple conjugates. So they're essentially regardless of if we're going to liver tissue or outside the liver. They're essentially
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |